Subscribe To
INRLF / Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race
INRLF News
By Seeking Alpha
October 4, 2023
Valneva's Vaccination Valor: A Buy Rating Justified
Valneva's 1H 2023 revenue declined compared to the previous year, but product sales more than doubled, driven by the recovery in the travel market. Th more_horizontal
By Reuters
September 7, 2023
Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shot
Pfizer and French pharmaceutical peer Valneva announced on Thursday that a phase 2 study for its VLA15 Lyme disease vaccine candidate showed a "strong more_horizontal
By Seeking Alpha
July 18, 2023
Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race
Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due t more_horizontal